RINGPU(SZ:300119)2025-08-26 01:10Group 1: Financial Performance - The company achieved a revenue of 1.708 billion CNY, a year-on-year increase of 20.53% [3] - Net profit attributable to the parent company reached 257 million CNY, reflecting a growth of 57.59% [3] - The net profit excluding non-recurring gains and losses was 188 million CNY, up 34.28% year-on-year [3] Group 2: Business Segments - The animal health business focused on major clients, significantly boosting revenue from biological products, which became a key growth driver [3] - The pet health segment generated 415 million CNY, a year-on-year increase of 17.94% [5] - The poultry segment saw a revenue of 611 million CNY, growing by 24.71% [9] Group 3: Research and Development - R&D investment reached 114 million CNY, accounting for 6.67% of revenue [3] - The company obtained 4 new veterinary drug registration certificates and 6 clinical trial approvals, including the world's first mRNA vaccine for food animals [3][8] - The R&D achievements contributed to the company's position in the global animal health industry [8] Group 4: Operational Efficiency - The company improved its gross margin by 2.36 percentage points, driven by revenue expansion and product structure optimization [4] - Lean transformation initiatives led to a reduction in sales and management expense ratio by 0.84 percentage points [4] - The raw material drug segment improved its gross margin by 14 percentage points, significantly reducing losses [6] Group 5: Strategic Initiatives - The company is enhancing its supply chain and product matrix in the pet health sector, with plans to launch new products such as cat interferon and probiotics [5] - Strategic partnerships with leading breeding groups are being developed to deepen service and cooperation [4] - The company is focusing on international market expansion and optimizing product structure to increase profitability [6]